EP2941272A1 - Formulation de lévothyroxine avec de la gomme arabique - Google Patents

Formulation de lévothyroxine avec de la gomme arabique

Info

Publication number
EP2941272A1
EP2941272A1 EP12814094.4A EP12814094A EP2941272A1 EP 2941272 A1 EP2941272 A1 EP 2941272A1 EP 12814094 A EP12814094 A EP 12814094A EP 2941272 A1 EP2941272 A1 EP 2941272A1
Authority
EP
European Patent Office
Prior art keywords
composition
acacia
thyroxine
propyl gallate
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12814094.4A
Other languages
German (de)
English (en)
Inventor
Baris E. POLAT
John Kirsch
Ramakrishna NALLAMOTHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Inc
Original Assignee
Mylan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Inc filed Critical Mylan Inc
Publication of EP2941272A1 publication Critical patent/EP2941272A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • Thyroxine active drugs are known for both therapeutic and prophylactic treatment of thyroid disorders.
  • levothyroxine sodium is prescribed for thyroid hormone replacement therapy in cases of reduced or absent thyroid function in, for example, ailments such as myxedema, cretinism and obesity.
  • Levothyroxine sodium is quite unstable, hygroscopic, and degrades rapidly when subjected to high humidity, light, or high temperature. See, for example, Won, Pharm. Res, 9(1):131-137, 1992.
  • U.S. Pat. No. 5,225,204 issued July 6, 1993, to Chen, et al, discloses a complex of levothyroxine sodium and a cellulose, polyvinylpyrrolidone or Poloxamer.
  • the formulation may be prepared by dissolving the drug complex in a polar organic solvent, adding a cellulose carrier to the liquid, and drying the resulting mixture to obtain a complex of levothyroxine sodium and polyvinylpyrrolidone or Poloxamer adsorbed on the cellulose carrier.
  • a pharmaceutical composition comprising thyroxine, acacia, and an antioxidant selected from propyl gallate, butylated hydroxyanisol, and butylated hydroxytoluene is disclosed.
  • the pharmaceutical composition has an improved shelf life.
  • the composition additionally comprises sucrose, microcrystalline cellulose, and mannitol.
  • R4 and R 5 may be the same or different and are selected from hydrogen; halogen; alkyl; aryl; cycloalkyl; heterocycloalkyl; amide; alcohol; acid; ester; ether; acyl; alkenyl; and alkynyl.
  • the thyroxine can be in the form of a free acid, a free base, an organic salt, an inorganic salt, or a hydrate.
  • Liothyronine is an example of a drug encompassed by the above-mentioned general formula.
  • the active ingredient in the composition is levothyroxine sodium.
  • the pharmaceutical comprises a therapeutically effective amount.
  • the dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide limits depending upon numerous factors such as the severity of the disease to be treated, the age and general health condition of the patient, other medicaments with which the patient is being treated, any side effects, and the preferences and experience of the medical practitioner involved.
  • a therapeutically effective dosage amount for thyroxine generally ranges from about 0.1 ⁇ g to about 5000 ⁇ g, such as from about 25 ⁇ g to about 300 ⁇ g.
  • the solid dosage forms contain the following compounds: levothyroxine sodium (active drug substance);
  • the final dosage forms comprises about 5% to about 70%, such as about 10% to about 60%, about 15% to about 50%, or about 15% to about 40% saccharide, by weight.
  • the saccharide is sucrose.
  • Further optional ingredients in the final dosage form may include a disintegrant, which if present, generally forms about 2% to about 30%, such as about 2% to about 15%, or about 3% to about 10% of the final formulation by weight.
  • lubricants are present in the final composition formulation at about 0.1% to about 5%, such as about 0.2% to about 3%, or about 0.5% to about 2.5% by weight.
  • Alditols which may be used in pharmaceutical compositions are well known in the art. Such alditols include, but are not limited to, one or more of the following:
  • saccharides for use in pharmaceutical compositions are well known in the art. Such saccharides include, but are not limited to, one or more monosaccharides, disaccharides, and oligosaccharides composed of 2-10 monosaccharides. Monosaccharides, also known as reducing sugars, include, but are not limited to, aldoses, hemiacetals, and cyclic hemiacetals. Disaccharides are generally defined as two monosaccharide units joined together by a glycoside linkage.
  • Oligosaccharides are generally defined as carbohydrates that hydro lyze to yield 2 to 10 molecules of a monosaccharide.
  • Monosaccharides, disaccharides, and oligosaccharides include, but are not limited to, sucrose, maltose, cellobiose, lactose, trehalose, glucose, fructose, galactose, ribose, or deoxyribose.
  • the saccharide is a monosaccharide or a disaccharide.
  • the saccharide is a disaccharide.
  • the saccharide is sucrose.
  • the mixture is then granulated by adding the propyl gallate, butylated hydroxyanisol, or butylated hydroxytoluene, and acacia solutions.
  • the granulated mixture is dried, cooled, then passed through a mill.
  • the acacia and thyroxine are blended together as dry ingredients.
  • excipients such as microcrystalline cellulose or dicalcium phosphate may also be incorporated into the granulation, but need not be added until the active ingredient is intimately mixed with the alditol and/or the sucrose.
  • compositions may be prepared for administration orally, rectally, vaginally, transmucosally, transdermally, parenterally, subcutaneously, and
  • excipients which are suitable for use in compositions for these methods of administration are known to those of skill in the art.
  • excipients contemplated for use in these compositions may include, but are not limited to, adjuvants, preservatives, buffers, fillers, extenders, carriers, binders, diluents, glidants, lubricants, surfactants, wetting agents, surface active agents, suspending agents, and solvents.
  • Compounds such as dyes and colorants, sweeteners, flavorings, perfuming agents, and taste-masking ingredients also may be included in compositions.
  • Any pharmaceutically acceptable excipient, such as ingredients to aid in processing, to improve taste, or to improve appearance are contemplated for use in this composition.
  • other active ingredients may be included to produce a dual or multiple active ingredient composition.
  • solid dosage forms examples include, but are not limited to, tablets, capsules, rectal or vaginal suppositories, pills, dragees, lozenges, granules, beads, microspheres, pellets, powders, or any combination thereof.
  • Formulations also may be prepared in the form of solutions, suspensions, emulsions, syrups, and elixirs. These liquid dosage forms may include liquid diluents in addition to the solid ingredients discussed above.
  • Such diluents may include, but are not limited to, solvents, solubilizing agents, suspending agents and emulsifiers, water or saline solutions, ethanol and other pharmaceutically acceptable alcohols, ethyl carbonate, ethyl acetate, propylene glycol, dimethyl formamide, pharmaceutically acceptable oils such as cottonseed, corn, olive, castor, and sesame, fatty acid esters of sorbitan, polyoxyethylene sorbitol, and agar-agar.
  • Formulations can be either immediate or modified release.
  • the composition may be used for any convenient dosage amount of the active ingredient. Generally, the level of the active ingredient may be increased or decreased according to the judgment of the physician, pharmacist, pharmaceutical scientist, or other person of skill in the art. The amount of the remaining non-active ingredients can be adjusted as needed. [0027] After the solid ingredients of the composition are blended, the composition may be compressed into tablets. Alternatively, the composition may be used to fill capsules such as hard gelatin capsules or used to prepare any other convenient solid dosage form.
  • compositions may be stored in the form of powders, granulates, intermediates, suspensions, or solutions prior to addition of additional desired pharmaceutical excipients for the production of final dosage forms such as tablets or solid-filled capsules, or final liquid dosage forms such as solutions, syrups, suspensions, emulsions and the like.
  • the pharmaceutical composition comprising thyroxine, acacia, and an antioxidant selected from propyl gallate, butylated hydroxyanisol, butylated hydroxytoluene, or combinations thereof has improved stability. Under accelerated testing conditions of 40°C at 75% relative humidity, the compositions retained about 95% to about 105% Theoretical Drug Content (TDC) after 6 months. In one embodiment, under accelerated testing conditions, the decrease in potency after 6 months is less than 5% such as less than 4%), less than 3%, or less than 2.5%. In another embodiment, the composition retained about 99% TDC after 6 months.
  • the stability of the pharmaceutical composition may also be tested at room temperature (25°C) at 60% relative humidity. In one embodiment, under the room temperature testing conditions the composition retained 95% to 105% TDC after 2 years.
  • microcrystalline cellulose, mannitol, and sucrose were screened or milled and then blended with levothyroxine sodium for about 6 minutes.
  • the wet granulation was dried at a temperature below 60°C until the moisture content was less than about 4%.
  • the dried granulation was sized by passing it through a mill, and then blended with the additional ingredients listed in the table below using conventional mixing equipment.
  • Levothyroxine 100 ⁇ g tablets were prepared using the following ingredients:

Abstract

La présente invention concerne une composition pharmaceutique comprenant de la thyroxine, de la gomme arabique, et un antioxydant choisi parmi le gallate de propyle, l'hydroxyanisol butylé et de l'hydroxytoluène butylé. La composition pharmaceutique a une durée de conservation améliorée. Dans un mode de réalisation, la composition comprend en outre du saccharose, de la cellulose microcristalline et du mannitol. La composition pharmaceutique peut être utilisée pour traiter des troubles de la thyroïde par administration par voie orale de la composition à un patient nécessitant cela.
EP12814094.4A 2012-12-21 2012-12-21 Formulation de lévothyroxine avec de la gomme arabique Withdrawn EP2941272A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/071184 WO2014098887A1 (fr) 2012-12-21 2012-12-21 Formulation de lévothyroxine avec de la gomme arabique

Publications (1)

Publication Number Publication Date
EP2941272A1 true EP2941272A1 (fr) 2015-11-11

Family

ID=47557525

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12814094.4A Withdrawn EP2941272A1 (fr) 2012-12-21 2012-12-21 Formulation de lévothyroxine avec de la gomme arabique

Country Status (2)

Country Link
EP (1) EP2941272A1 (fr)
WO (1) WO2014098887A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316206D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2014098887A1 *

Also Published As

Publication number Publication date
WO2014098887A1 (fr) 2014-06-26

Similar Documents

Publication Publication Date Title
US6645526B2 (en) Storage stable thyroxine active drug formulations and methods for their production
EP2566462B1 (fr) Formulations à libération immédiate et formes pharmaceutiques de gamma-hydroxybutyrate
CA2740146C (fr) Formes posologiques a liberation immediate d'oxybate de sodium
CA2703313C (fr) Formes galeniques orales renfermant de l'acetate de licarbazepine
US7052717B2 (en) Storage stable thyroxine active drug formulations and methods for their production
JPH10194969A (ja) 錠剤組成物
KR20110097936A (ko) 울리프리스탈 아세테이트 정제
WO2011010324A1 (fr) Compositions pharmaceutiques orales stables comprenant de la rasagiline et procédé
JP2019112424A (ja) トホグリフロジンを含有する固形製剤及びその製造方法
US20180325852A1 (en) Alditol-free, storage-stable thyroid hormone active drug formulations and methods for their production
US8779000B1 (en) Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
JP7104039B2 (ja) 医薬組成物
US9271951B2 (en) Levothyroxine formulation with acacia
US20140179784A1 (en) Levothyroxine formulation with carrageenan
US20050069584A1 (en) Diphenhydramine tannate solid dose compositions and methods of use
EP2941272A1 (fr) Formulation de lévothyroxine avec de la gomme arabique
KR101244627B1 (ko) 올란자핀을 함유하는 확산정 조성물 및 이에 의해 형성된 정제
WO2010010367A1 (fr) Composition pharmaceutique solide contenant de l'exémestane
WO2014098886A1 (fr) Formulation de lévothyroxine avec de la carraghénine
WO2020045607A1 (fr) Composition pharmaceutique pour administration par voie orale
KR101609105B1 (ko) 용출성 및/또는 흡수성이 개선된 경구 투여용 의약 조성물
WO2013168032A1 (fr) Compositions pharmaceutiques contenant de la rasagiline
EP2976067B1 (fr) Composition pharmaceutique comprenant un agent antibactérien de fluoroquinolone et son procédé de préparation
JP7093534B2 (ja) ヨクイニンを含むプレミックスエキス及びその利用
HU225779B1 (en) Pharmaceutical composition containing paracetamol and drotaverine and process for producing it

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150716

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/198 20060101ALI20161121BHEP

Ipc: A61K 47/10 20060101AFI20161121BHEP

Ipc: A61K 9/20 20060101ALI20161121BHEP

Ipc: A61K 47/14 20060101ALI20161121BHEP

INTG Intention to grant announced

Effective date: 20161207

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

INTC Intention to grant announced (deleted)
17Q First examination report despatched

Effective date: 20170915

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20190517

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190928